R&D - Luye Pharma Group

R&D centers

Located in China, the United States and Europe

Robust R&D pipelines of drug candidates:

30⁺ in China

10⁺ overseas

Nearly 800

R&D professionals

R&D Centers

R&D Center in China

Key R&D Capabilities

Long-acting and Extended Release Technology

Liposome and Targeted Drug Delivery Technology

New Molecular Entity Platforms

Biological Antibody Platforms

R&D Center in the U.S.

Key R&D Capabilities

International R&D Collaboration

Exploratory Study for Innovative Drugs

R&D Center in Europe

Key R&D Capabilities

Transdermal Drug Delivery Technology

Granted Patents

251 patents granted in China

577 patents granted overseas

（As of December 2025）

Platforms and Technologies

NDDS

Novel Drug Delivery Systems (NDDS)

• Long-acting and extended release technology;

• Liposome and targeted drug delivery technology;

• Transdermal drug delivery technology;

NME

New Molecular Entities (NME)

• New Chemical Entities (NCE): They include small molecules and nucleic acid therapeutics focusing on novel targets;

• PROTAC: It enables complete target protein degradation, overcomes drug resistance, and addresses traditionally undruggable targets;

• RIPTAC: It adopts a "lock-and-kill" strategy to selectively eliminate tumor cells;

• Cyclic Peptide: Designed for protein-protein interactions (PPI) and other undruggable targets.

Antibodies

BA-huMab^®Fully Human Antibody Platform

• It covers almost all genes in the human antibody κ light chain variable region and in the human heavy chain variable region (IgM and IgG1);

• No humanization required, this platform enables high antibody affinity and low immunogenicity;

• It’s been validated in more than 10 investigational antibody programs.

Antibodies

Bispecific / Multispecific Antibody / Probody Platform

• On this platform, we develop next-generation PD-(L)1-based ICIs (e.g., PD-1/IL-2 immunocytokines) to address low response rates and resistance associated with conventional ICIs;

• Multiple bispecific and multispecific antibody programs are under development to treat cancers and autoimmune diseases;

• It reduces on-target toxicity in non-tumor tissues through Probody and masking peptide technologies, thereby expanding the therapeutic window.

Antibodies

Antibody-Drug Conjugate (ADC) Platform

• It utilizes novel payloads with excellent therapeutic potential;

• Glycosite-specific conjugation is used to improve the safety profile;

• On this platform, we develop novel bispecific ADCs to address highly heterogeneous tumors;

• We also develop innovative dual-payload ADCs to overcome drug resistance;

• Multiple bispecific ADC and dual-payload ADC programs are under development;

• Probody ADCs are under development.

R&D Pipelines

NME

New Molecular Entities (NME)

• New Chemical Entities (NCE): They include small molecules and nucleic acid therapeutics focusing on novel targets;

• PROTAC: It enables complete target protein degradation, overcomes drug resistance, and addresses traditionally undruggable targets;

• RIPTAC: It adopts a "lock-and-kill" strategy to selectively eliminate tumor cells;

• Cyclic Peptide: Designed for protein-protein interactions (PPI) and other undruggable targets.

Antibodies

BA-huMab^®Fully Human Antibody Platform

• It covers almost all genes in the human antibody κ light chain variable region and in the human heavy chain variable region (IgM and IgG1);

• No humanization required, this platform enables high antibody affinity and low immunogenicity;

• It’s been validated in more than 10 investigational antibody programs.

Antibodies

Bispecific / Multispecific Antibody / Probody Platform

• On this platform, we develop next-generation PD-(L)1-based ICIs (e.g., PD-1/IL-2 immunocytokines) to address low response rates and resistance associated with conventional ICIs;

• Multiple bispecific and multispecific antibody programs are under development to treat cancers and autoimmune diseases;

• It reduces on-target toxicity in non-tumor tissues through Probody and masking peptide technologies, thereby expanding the therapeutic window.

Antibodies

Antibody-Drug Conjugate (ADC) Platform

• It utilizes novel payloads with excellent therapeutic potential;

• Glycosite-specific conjugation is used to improve the safety profile;

• On this platform, we develop novel bispecific ADCs to address highly heterogeneous tumors;

• We also develop innovative dual-payload ADCs to overcome drug resistance;

• Multiple bispecific ADC and dual-payload ADC programs are under development;

• Probody ADCs are under development.